TrialThe Journal of dermatology2021

Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.

Akimichi Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.